Question and answers - Addressing cardiovascular risk in type 2 diabetes - The LEADER trial.

28 August 2016 (19:25 - 20:00)

Organised by:

About the speaker

Professor Lars Ryden

Karolinska Institute, Stockholm (Sweden)

4 More presentations in this session

Presentation thumbnail

Introduction - Cardiovascular risk in diabetes and cardiovascular outcomes trials - Where do we come from?

Professor L. Ryden (Stockholm, SE)

Presentation thumbnail

LEADER – Cardiovascular outcomes & the cardiologist’s perspective.

Professor S. Nissen (Cleveland, US)

Presentation thumbnail

LEADER from the diabetologist’s perspective.

Professor J. Petrie (Glasgow, GB)

Presentation thumbnail

Cardiovascular outcomes trials in diabetes – What have we learned?

Doctor M. Husain (Toronto, CA)

Access the full session

Session thumbnail

Addressing cardiovascular risk in type 2 diabetes - The LEADER trial

The Event

ESC Congress 2016

28 August 2016 19:25 CET

You may be interested in

Congress Session

Guidelines in Practice: 2023 ESC Guidelines for the Management of Cardiovascular Disease in Patients with Diabetes

27 August 2023

Congress Presentation

Glucose lowering drugs or strategies, major adverse cardiovascular events and heart failure outcomes, and association with weight loss - meta-analysis of large cardiovascular outcome trials

2 September 2019

Congress Presentation

Effects of semaglutide on functional capacity in patients with type 2 diabetes and peripheral arterial disease: rationale and design of the STRIDE trial

27 August 2021

Congress Presentation

Qualifying event proximity, cardiovascular risk, and benefit of empagliflozin in patients with type 2 diabetes and stable atherosclerosis in the EMPA-REG OUTCOME trial

31 August 2019

ESC 365 is supported by

novartis

Explore sponsored resources

novo-nordisk

Explore sponsored resources

ESC 365 is supported by

novartis

Explore sponsored resources

novo-nordisk

Explore sponsored resources